NextCure (NASDAQ:NXTC) Major Shareholder Adar1 Capital Management, Llc Acquires 3,553 Shares of Company Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc acquired 3,553 shares of the stock in a transaction dated Tuesday, October 27th. The stock was acquired at an average price of $5.10 per share, for a total transaction of $18,120.30. Following the completion of the transaction, the insider directly owned 733,270 shares of the company’s stock, valued at approximately $3,739,677. This represents a 0.49% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Monday, October 26th, Adar1 Capital Management, Llc acquired 1,672 shares of NextCure stock. The stock was acquired at an average cost of $5.03 per share, with a total value of $8,410.16.
• On Friday, October 23rd, Adar1 Capital Management, Llc bought 5,626 shares of NextCure stock. The shares were acquired at an average price of $4.83 per share, with a total value of $27,173.58.
• On Friday, July 31st, Adar1 Capital Management, Llc bought 36,303 shares of NextCure stock. The shares were acquired at an average price of $4.94 per share, with a total value of $179,336.82.
• On Thursday, July 30th, Adar1 Capital Management, Llc bought 292,850 shares of NextCure stock. The shares were acquired at an average cost of $4.93 per share, for a total transaction of $1,443,750.50.
• On Wednesday, July 29th, Adar1 Capital Management, Llc bought 3,410 shares of NextCure stock. The shares were acquired at an average cost of $5.00 per share, for a total transaction of $17,050.00.

NextCure Stock Up 9.6%

NASDAQ NXTC traded up $0.50 during trading hours on Tuesday, reaching $5.72. The company’s stock had a trading volume of 142,082 shares. The firm’s 50-day moving average price is $6.11 and its 200-day moving average price is $7.99. NextCure, Inc. has a 1 year low of $1.55 and a 1 year high of $15.74.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($2.80) earnings per share for the quarter, missing the consensus estimate of ($1.95) by ($0.85).

Analysts Set New Price Targets

NXTC has been the subject of a number of research reports. Wall Street Zen upgraded shares of NextCure from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. HC Wainwright reaffirmed a “buy” rating on shares of NextCure in a research note on Thursday, August 13th. Finally, Weiss Ratings downgraded shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, NextCure currently has a consensus rating of “Hold” and a consensus target price of $19.00.

Hedge Funds Weigh In On NextCure

A hedge fund recently raised its position in NextCure stock. Renaissance Technologies LLC raised its position in shares of NextCure, Inc. (NASDAQ:NXTC) by 80.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,534 shares of the company’s stock after acquiring an additional 26,900 shares during the period. Renaissance Technologies LLC owned approximately 1.68% of NextCure worth $647,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells.

NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.

Founded in 2015 and headquartered in the United States, NextCure has operated primarily as a research and development company serving the global oncology market through clinical trials and collaborations.